Advertisements

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Stock Quote

Detailed Quote for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
$ 1.27   -0.065 (-4.87%) Volume: 27.62k 3:59 PM EDT Sep 21, 2018
Today 5d 1m 3m 1y more
Last Price
1.27
Change $
0.065
Change %
4.87%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
1.3135
High
1.3215
Low
1.27
Prev Close
1.335
Last Trade
09/21/18
Volume
27.62k
52 Wk Hi
2.75
52 Wk Low
1.12
Market Cap
25.63m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
20,181,145
EPS (TTM)
-0.25999999
PE Ratio
N/A
Exchange
NYSE American
News and Media for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
Sector News | Topic News
News for Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF)
Wed, Sep 12, 2018
7:00 AM Can-Fite to Present the Anti-Fibrogenic Effects of Namodenoson at the Hepatic Fibrosis Conference of the American Association for the Study of Liver Diseases (AASLD) - Business Wire
Tue, Sep 04, 2018
9:24 AM Premarket Gainers as of 9:05 am (9/4/2018) - SeekingAlpha
7:00 AM Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected by End of Year - Business Wire
Fri, Aug 31, 2018
7:21 AM Can-Fite Biopharma net loss improves in 1H - SeekingAlpha
7:02 AM Can-Fite Biopharma reports 1H results - SeekingAlpha
7:00 AM Can-Fite Reports Second Quarter 2018 Financial Results and Provides Clinical Update - Business Wire
Wed, Aug 29, 2018
7:00 AM Can-Fite BioPharma Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 - Business Wire
Tue, Aug 21, 2018
7:46 AM Can-Fite enrolls first patient in its Comfort Phase III trial of Piclidenoson in Psoriasis - SeekingAlpha
7:00 AM Can-Fite Announces Enrollment of First Patient in its Comfort(TM) Phase III Trial of Piclidenoson in Psoriasis - Business Wire
Sun, Aug 12, 2018
3:36 PM Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO - SeekingAlpha
Tue, Aug 07, 2018
9:14 AM Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China - Business Wire
Mon, Aug 06, 2018
9:15 AM Premarket Gainers as of 9:05 am (08/06/2018) - SeekingAlpha
5:54 AM Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical - Business Wire
Tue, Jul 17, 2018
7:39 AM Can-Fite granted Australian and Chinese patents for erectile dysfunction drug, shares up 5.7% premarket - SeekingAlpha
7:00 AM Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug - Business Wire
Mon, Jul 02, 2018
7:00 AM Drugs with Mechanism of Action Utilized by Namodenoson Are Recommended by Leading U.S. Researchers to Be Developed to Combat Liver Cancer - Business Wire
Thu, Jun 21, 2018
8:00 AM Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges - SeekingAlpha
Tue, Jun 19, 2018
9:16 AM Premarket Gainers as of 9:05 am (06/19/2018) - SeekingAlpha
7:00 AM Can-Fite Updates on Status of Phase II Advanced Liver Cancer Trial - Business Wire
Wed, Jun 13, 2018
6:00 PM Your Daily Pharma Scoop: Tetraphase Positive Data, MediWound In Phase 3, Allergan Moves Up - SeekingAlpha
More News for CANF >>

Tags for Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Research stocks or mutual funds related to Can-Fite Biopharma Ltd Sponsored ADR (Israel) by keywords or tags. Find companies that have a similar focus to CANF. The keywords below have been associated to CANF by either user submission or electronic means.